Recent News

• 04.25.2025 - ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
• 04.25.2025 - ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
• 04.25.2025 - ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints
• 04.25.2025 - ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints
• 04.07.2025 - ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
• 04.07.2025 - ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
• 03.06.2025 - ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
• 03.06.2025 - ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Recent Filings

• 04.24.2025 - EFFECT Notice of Effectiveness
• 04.21.2025 - ARS Annual Report to Security Holders
• 04.21.2025 - DEF 14A Other definitive proxy statements
• 04.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.06.2025 - S-3 Registration statement under Securities Act of 1933